Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Henry Yu

Physician Assistant Bronx, NY Physician Assistant

NPI 1629043096 CMS profile 10434676

2426 Eastchester Rd Ste 212, Bronx, NY 10469

Open in the dashboard

General payments

$1,002,269

2,666 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Henry Yu of Bronx, NY is reported in the CMS Open Payments database as having received $1,002,269 across 2,666 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $307,092 644
2024 General $305,774 651
2023 General $252,032 675
2022 General $90,701 418
2021 General $46,670 278

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Henry Yu
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Henry Yu were reported at $307,092. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Henry Yu Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $46,670 $132 $37–$438 $132
2022 $90,701 $155 $48–$522 $149
2023 $252,032 $167 $52–$557 $160
2024 $305,774 $178 $55–$600 $164
2025 $307,092 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. UCB, Inc. $258,368 521 payments
  2. LEO Pharma Inc. $143,014 337 payments
  3. Pfizer Inc. $111,402 164 payments
  4. Janssen Biotech, Inc. $90,921 223 payments
  5. AbbVie, Inc. $73,156 263 payments
  6. Galderma Laboratories, L.P. $72,001 214 payments
  7. Dermavant Sciences, Inc. $67,533 160 payments
  8. Arcutis Biotherapeutics, Inc. $54,018 206 payments
  9. Sun Pharmaceutical Industries Inc. $25,004 109 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $23,782 29 payments
  11. Other $83,071 440 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $620,351 449 payments
  2. Consulting Fee $178,999 196 payments
  3. Travel and Lodging $134,044 449 payments
  4. Food and Beverage $53,132 1,554 payments
  5. Honoraria $13,229 13 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $2,171 1 payment
  7. Education $342 4 payments
Products named General payments · program years 2021–2025
  1. Bimzelx $154,666 272 payments
  2. ADBRY $107,690 248 payments
  3. TREMFYA $97,017 241 payments
  4. CIBINQO $85,581 134 payments
  5. RINVOQ $68,410 207 payments
  6. VTAMA $67,027 165 payments
  7. Zoryve $47,522 163 payments
  8. ANZUPGO $37,637 73 payments
  9. AKLIEF $32,977 86 payments
  10. Cimzia $29,240 109 payments
  11. Other $217,641 1,090 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

2,050

Median for Physician Assistant: 241

Drug cost

$4,665,336

Median for Physician Assistant: $4,110

Branded share of claims

68.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Bimzelx Bimekizumab-Bkzx Brand 42 $583,453
Dupixent Syringe Dupilumab Brand 147 $550,904
Ilumya Tildrakizumab-Asmn Brand 26 $439,241
Tremfya Guselkumab Brand 32 $427,949
Opzelura Ruxolitinib Phosphate Brand 198 $413,164
Skyrizi Risankizumab-Rzaa Brand 19 $396,727
Adbry Tralokinumab-Ldrm Brand 109 $374,231
Rinvoq Upadacitinib Brand 50 $328,050
Vtama Tapinarof Brand 194 $274,606
Zoryve Roflumilast Brand 264 $230,106

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Bimzelx
$67,946 42 —
TREMFYA
$44,229 32 —
CIBINQO
$36,285 32 —
RINVOQ
$27,014 50 —
ADBRY
$24,270 129 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

2,666 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record